Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Childs Nerv Syst ; 24(2): 225-30, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17710418

RESUMEN

OBJECTS: Perform neuropsychological screening of a group of preterm twins without major brain pathology and compare it with a control group of similarly preterm children born as singletons. MATERIALS AND METHODS: Twenty-three preterm twins born at fewer than 32 weeks of gestation were tested for rapid evaluation of cognitive functions at the age of 4 years. The tests evaluated language, non-verbal performances, learning and attention deficit disorders. Cognitive profiles were established. Links between perinatal factors, clinical follow-up and cognitive outcome were investigated. Their cognitive outcome was then compared with the cognitive outcome of 31 preterm singletons with the same gestational periods. CONCLUSION: The twins' neuropsychological outcome was not more marked than that of the singletons. Birth weight discordance and chorionicity were the only predictive perinatal factors with worse outcome in the twin population.


Asunto(s)
Cognición/fisiología , Discapacidades del Desarrollo/epidemiología , Enfermedades en Gemelos/epidemiología , Enfermedades del Prematuro/epidemiología , Gemelos/fisiología , Peso al Nacer , Niño , Preescolar , Femenino , Humanos , Recién Nacido , Masculino , Pruebas Neuropsicológicas , Embarazo , Nacimiento Prematuro
2.
Fetal Diagn Ther ; 17(1): 22-4, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-11803211

RESUMEN

We report the effects of recombinant human erythropoietin (rHuEPO) in the treatment of late hyporegenerative anemia in 2 neonates with Rh hemolytic disease who had received several in utero exchange transfusions. In both cases anemia occurred at 6 weeks of age and we started therapy at approximately 70 days of age. We used rHuEPO at 250 U/kg three times a week. We also used high-dose intravenous immunoglobulin therapy. One week after initiation of erythropoietin treatment, an increase in reticulocyte count and Hb level was noted in our 2 patients. They did not require further erythrocyte transfusions but they already had received two transfusions after birth. There were no side effects attributable to rHuEPO treatment.


Asunto(s)
Anemia Aplásica/complicaciones , Anemia Aplásica/tratamiento farmacológico , Transfusión de Sangre Intrauterina , Eritropoyetina/uso terapéutico , Recambio Total de Sangre , Proteínas Recombinantes/uso terapéutico , Isoinmunización Rh/complicaciones , Isoinmunización Rh/terapia , Humanos , Recién Nacido , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA